Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00729664 · ClinicalTrials.gov registry record · Phase 1
Multiple Ascending Dose (MDX1105-01)
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 281
- Enrollment target
NCT00729664 is a Phase 1 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 281 participants.
The verdict
NCT00729664, a Phase 1 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 281 participants
- Enrollment target
Study Summary
Collection of survival data, evaluation of PDL-1 expression in tumors, and evaluation of PD-L1 receptor occupancy in peripheral blood has been added.
Interventions
- BIOLOGICAL Anti-PDL-1 antibody
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 281 participants |
| Start Date | 2009-02 |
| Est. Completion | 2015-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00729664
The ClinicalTrials.gov registry entry for NCT00729664 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 281 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Anti-PDL-1 antibody is the first listed.
NCT00729664 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00729664 about?
NCT00729664 is a clinical study titled "Multiple Ascending Dose (MDX1105-01)". Collection of survival data, evaluation of PDL-1 expression in tumors, and evaluation of PD-L1 receptor occupancy in peripheral blood has been added.
What is the current status of trial NCT00729664?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 281 participants. The study started on 2009-02. Estimated completion is 2015-07.
What interventions are being tested in trial NCT00729664?
The interventions under investigation include: Anti-PDL-1 antibody (BIOLOGICAL).
Who is sponsoring clinical trial NCT00729664?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.